Showing posts with label alzheimer's clinical trial. Show all posts
Showing posts with label alzheimer's clinical trial. Show all posts

Monday, January 21, 2013

Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease




Caregivers and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

ClinicalTrials.gov

This is a 24 week study with 14 visits to the research clinic. Approximately 6 of these visits may be done by phone. Additional phone checks are scheduled at the beginning of each 12 week part of the study. Participants will have a 50:50 chance of being on prazosin or placebo in the first 12 weeks of the study. For the second 12 weeks, all participants will take prazosin.
Study visits include a physical and neurological exam; memory testing; interviews with the caregiver about behaviors; and vital signs.
  Eligibility
Genders Eligible for Study:  Both
Accepts Healthy Volunteers:  No
Criteria
Inclusion Criteria:
  • No age limit
  • Probable or Possible Alzheimer's Disease
  • Disruptive agitated behaviors at least twice a week (overly anxious or excited, making offensive comments.....)
  • Stable medications for 2 weeks
  • Must have a caregiver who spends 10 hours per week caring for the participant and agrees to participate in all evaluation sessions
Exclusion Criteria:
  • Cardiovascular: unstable angina, recent myocardial infarction, preexisting hypotension (systolic BP less than 110) or orthostatic hypotension (≥20 mmHg drop in systolic BP following 2 minutes of standing posture)
  • Any unstable medical condition
  • Exclusionary medications: current treatment with prazosin, other alpha-1 blockers (trazodone, sildenafil, vardenafil or tadalafil)
  • Psychoactive medications: subjects may be psychoactive medication-free or be partial responders (by subjective assessment of referring health care professional) to one psychoactive medication from any of the following classes: antipsychotics, anticonvulsants, mood stabilizers, antidepressants, benzodiazepines, or buspirone. Partial response is defined as some improvement in agitated behavior but persistence of agitated behaviors severe enough to cause patient distress and/or difficulty with caregiving. Although not formally rated, this improvement is equivalent to a Clinical Global Impression of Change rating of no more than minimal improvement (improvement is noticed by not enough to improve patient function or caregiver's practical management of the patient).
  • Psychiatric/behavioral: lifetime schizophrenia; current delirium, mania, depression, or uncontrolled persistent distressing psychotic symptoms (hallucinations, delusions), substance abuse, panic disorder, or any behavior which poses an immediate danger to patient or others or which results in the patient being too uncooperative to meet the requirements of study participation.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01126099
Contacts
Contact: Lucy Wang, MD(206) 277-5089wanglucy@u.washington.edu
Contact: Kirsten Rohde, RN(206) 764-2713kirsten.rohde@va.gov

Wednesday, July 25, 2012

Alzheimer's drug fails in one study; second continues


Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

USA Today
TRENTON, N.J. (AP) – Pfizer Inc. said Monday that a closely watched experimental Alzheimer's drug failed to slow the disease in one late-stage study, but the drug maker said it will continue to study the drug's effect on a different group of patients.

Pfizer, which is testing bapineuzumab with partner Johnson & Johnson, said the injected drug didn't slow mental or functional decline in patients with mild or moderate Alzheimer's disease. The study included patients who carry a gene called ApoE4, which gives people a higher risk of developing the memory-robbing disorder.



About half the population does not carry that gene, however, and Pfizer says a study of the drug in patients without the gene is continuing. Results of that study are expected to be announced later this summer.






Johnson & Johnson spokeswoman Ellen Rose said scientists who conducted mid-stage tests on bapineuzumab "saw a hint that the people who are carriers of the ApoE4 gene might not have as good a chance as people who are not carriers."


New York-based Pfizer and Johnson & Johnson, based in New Brunswick, N.J., are each running two studies of the experimental drug.


Current medicines for Alzheimer's disease temporarily control symptoms such as memory loss, confusion and agitation. But they do nothing to slow, stop or reverse mental decline, leaving patients and their loved ones desperate for a new treatment.


Finding a drug that could at least slow the disease has become a sort of Holy Grail in the pharmaceutical industry. A successful medicine would be guaranteed to generate billions in annual sales, given the world's aging population.

Wednesday, May 30, 2012

Successful Alzheimer's drug trial


Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire




Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition



Reuters



 Danish drugmaker Lundbeck said patients who took its Alzheimer's drug candidate Lu AE58054 in a phase 2 clinical trial achieved statistically significant improvement in cognitive performance when the compound was added to donepezil.

Lundbeck said the clinical study in 278 patients suffering from Alzheimer's disease had achieved its main target and that Lu AE58054 was also well-tolerated in combination with donepezil.

"These results are very encouraging, and we are now evaluating how to best proceed with the development of Lu AE58054," Anders Pedersen, head of research and development at Lundbeck, said in the statement.

Lundbeck said Alzheimer's disease affects over 26 million people worldwide, and the cost to society has been reported as $600 billion per year
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info